• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Introduction to 2,3-dimethyl-2H-indazole (CAS No. 50407-18-6)

2,3-dimethyl-2H-indazole, identified by the Chemical Abstracts Service Number (CAS No.) 50407-18-6, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the indazole class, characterized by a fused benzene and pyridine ring system, with additional substituents that modulate its chemical and biological properties. The structural features of 2,3-dimethyl-2H-indazole make it a versatile scaffold for the development of novel therapeutic agents.

The indazole core is a privileged structure in drug discovery, known for its broad spectrum of biological activities. Compounds derived from indazole have been explored for their potential in treating various diseases, including cancer, infectious diseases, and neurological disorders. The presence of methyl groups at the 2 and 3 positions in 2,3-dimethyl-2H-indazole enhances its stability and influences its interaction with biological targets. This modification has been strategically employed to improve pharmacokinetic profiles and binding affinity.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the binding modes of 2,3-dimethyl-2H-indazole with target proteins with high precision. These studies have revealed that the compound can interact with enzymes and receptors involved in critical cellular pathways. For instance, research suggests that 2,3-dimethyl-2H-indazole may inhibit kinases and other enzymes implicated in tumor proliferation and survival. This finding aligns with the growing interest in developing small-molecule inhibitors as anticancer agents.

In addition to its potential as an anticancer agent, 2,3-dimethyl-2H-indazole has been investigated for its antimicrobial properties. Preliminary studies indicate that the compound exhibits activity against certain resistant bacterial strains. The mechanism of action likely involves disruption of bacterial cell wall synthesis or interference with essential metabolic pathways. These findings are particularly relevant in the context of rising antibiotic resistance, where novel antimicrobial strategies are urgently needed.

The synthesis of 2,3-dimethyl-2H-indazole involves multi-step organic reactions that require careful optimization to achieve high yields and purity. Common synthetic routes include cyclization reactions followed by functional group modifications. Advances in green chemistry have also led to the development of more sustainable synthetic methods for indazole derivatives. For example, catalytic processes that minimize waste and energy consumption have been reported in recent literature.

The pharmacological evaluation of 2,3-dimethyl-2H-indazole has been conducted using both in vitro and in vivo models. In cell-based assays, the compound has demonstrated promising effects on various disease-relevant pathways. Animal studies have further supported these findings by showing therapeutic efficacy in models of cancer and inflammation. These preclinical results provide a strong rationale for further exploration of 2,3-dimethyl-2H-indazole as a lead compound for drug development.

One of the key challenges in translating preclinical findings into clinical applications is understanding the metabolic fate of indazole derivatives. Studies using mass spectrometry and other analytical techniques have provided insights into how 2,3-dimethyl-2H-indazole is metabolized in vivo. These data are crucial for predicting drug-drug interactions and optimizing dosing regimens. Additionally, pharmacokinetic studies have helped identify potential modifications to enhance bioavailability and prolong systemic exposure.

The future direction of research on 2,3-dimethyl-2H-indazole includes exploring structure-activity relationships (SAR) to identify more potent analogs. By systematically modifying different parts of the molecule, researchers can fine-tune its biological activity while minimizing side effects. Collaborative efforts between academic institutions and pharmaceutical companies are essential to accelerate this process.

The role of high-throughput screening (HTS) technologies cannot be overstated in the discovery of novel drug candidates like 2,3-dimethyl-2H-indazole. HTS allows for rapid testing of large libraries of compounds against numerous biological targets, thereby identifying promising leads for further optimization. Integration with artificial intelligence (AI) tools has further enhanced HTS by enabling more accurate predictions of compound efficacy and toxicity.

In conclusion, 2,3-dimethyl-2H-indazole (CAS No. 50407-18-6) represents a promising scaffold for developing new therapeutic agents with applications in oncology and antimicrobial therapy. The structural features and biological activities make it an attractive candidate for further exploration under both academic and industrial settings.

• 58536-48-4((2-Methyl-2H-indazol-3-yl)methanol)
• 34252-54-5(2-Methyl-2H-indazole-3-carbaldehyde)
• 444731-72-0(2,3-Dimethyl-2H-indazol-6-amine)
• 7388-95-6(Cinnolinium, 2,3-dimethyl-, iodide)
• 58706-38-0(2H-Indazole, 2,3,7-trimethyl-)
• 58706-42-6(2H-Indazole, 3-ethyl-2-methyl-)
• 635702-60-2(2,3-Dimethyl-2H-indazol-6-amine hydrochloride)
• 31748-45-5(3-Cyano-2-methyl-2H-indazole)
• 34879-84-0(1,3-Dimethyl-1H-indazole)
• 878064-16-5(5-Bromo-2,3-dimethyl-2H-indazole)